Fundz

Barinthus to merge with Clywedog for new firm

TAKEN PRIVATEMar 13, 2026

Acquiring Company

Barinthus Biotherapeutics plc

Acquired Company

Clywedog Therapeutics

OxfordBiotechnologyTherapeuticsBiopharma

Description

Barinthus Biotherapeutics is set to merge with Clywedog Therapeutics to form a new company focused on autoimmune and metabolic diseases. This merger is projected to provide a cash runway through 2027, enhancing research and development capacities.

Who to call at Barinthus Biotherapeutics plc, and when

When Barinthus Biotherapeutics plc changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Barinthus Biotherapeutics plc raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Barinthus Biotherapeutics plc, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Barinthus Biotherapeutics plc

Location

Oxford, England, United Kingdom

About

Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP; Barinthus Bio is advancing a pipeline of four product candidates across a diverse range of therapeutic areas.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Barinthus Biotherapeutics plc makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Nick
Senior decision-maker at this company
••••••••@••••••••

See Nick's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Barinthus Biotherapeutics plc's next move

Learn about Strategic plan

Frequently asked

Who acquired Clywedog Therapeutics?

Clywedog Therapeutics was acquired by Barinthus Biotherapeutics plc, based in Oxford. The deal was reported on March 13, 2026. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Barinthus Biotherapeutics plc is privately held and operates in Biotechnology.

When did Barinthus Biotherapeutics plc acquire Clywedog Therapeutics?

Barinthus Biotherapeutics plc's acquisition of Clywedog Therapeutics was reported on March 13, 2026. Barinthus Biotherapeutics is set to merge with Clywedog Therapeutics to form a new company focused on autoimmune and metabolic diseases. This merger is projected to provide a cash runway through 2027, enhancing research and development capacities. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Clywedog Therapeutics do?

Clywedog Therapeutics is the company acquired in this transaction. It is privately held.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.